Search

Your search keyword '"González‐Ruiz, Lucía"' showing total 3 results
Start Over Author "González‐Ruiz, Lucía" Topic systematic review Publisher mdpi
3 results on '"González‐Ruiz, Lucía"'

1. Prognostic and Clinicopathological Significance of CCND1/Cyclin D1 Upregulation in Melanomas: A Systematic Review and Comprehensive Meta-Analysis

Author

González-Ruiz, Lucía, González-Moles, Miguel Ángel, González-Ruiz, Isabel, Ruiz-Ávila, Isabel, Ramos-García, Pablo, [González-Ruiz,L] Dermatology Service, Ciudad Real General University Hospital, Ciudad Real, Spain. [González-Moles,MÁ, González-Ruiz,I, Ramos-García,P] School of Dentistry, University of Granada, Granada, Spain. [González-Moles,MÁ, Ruiz-Ávila,I, and Ramos-García,P] Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. [González-Moles,MÁ] WHO Collaborating Group for Oral Cancer, Geneva, Switzerland. [Ruiz-Ávila,I] Pathology Service, San Cecilio Hospital Complex, Granada, Spain.

Subjects
Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Pharmacological Processes::Up-Regulation [Medical Subject Headings], Revisión sistemática, Amplificación génica, Pronóstico, Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression Regulation::Gene Amplification [Medical Subject Headings], Ciclina D1, CCND1, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Meta-analysis, Information Science::Information Science::Medical Informatics::Medical Informatics Applications::Information Systems::Databases as Topic::Databases, Bibliographic [Medical Subject Headings], Publication Type::Study Characteristics::Meta-Analysis [Medical Subject Headings], Systematic review, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings], Cyclin D1, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intracellular Signaling Peptides and Proteins::Cyclins::Cyclin D::Cyclin D1 [Medical Subject Headings], Metaanálisis, Melanoma, Diseases::Neoplasms::Neoplasms by Histologic Type::Nevi and Melanomas::Melanoma [Medical Subject Headings]
Abstract

Our objective was to evaluate the prognostic and clinicopathological significance of cyclin D1 (CD1) overexpression/CCND1 amplification in melanomas. We searched studies published before September 2019 (PubMed, Embase, Web of Science, Scopus). We evaluated the quality of the studies included (QUIPS tool). The impact of CD1 overexpression/CCND1 amplification on overall survival and relevant clinicopathological characteristic were meta-analyzed. We performed heterogeneity, sensitivity, small-study effects, and subgroup analyses. Forty-one studies and 3451 patients met inclusion criteria. Qualitative evaluation demonstrated that not all studies were performed with the same rigor, finding the greatest risk of bias in the study confounding domain. Quantitative evaluation showed that immunohistochemical CD1 overexpression had a statistical association with Breslow thickness (p = 0.007; OR = 2.09,95% CI = 1.23-3.57), significantly higher frequency of CCND1/cyclin D1 abnormalities has been observed in the primary tumor compared to distant metastases (p = 0.004), revealed also by immunohistochemical overexpression of the protein (p < 0.001; OR = 0.53,95% CI = 0.40-0.71), while the CCND1 gene amplification does not show association (p = 0.43); while gene amplification, on the contrary, appeared more frequently in distant metastases (p = 0.04; OR = 1.70,95% CI = 1.01-2.85) and not in the primary tumor. In conclusion, CCND1/cyclin D1 upregulation is a common molecular oncogenic alteration in melanomas that probably favors the growth and expansion of the primary tumor. This upregulation is mainly consequence to the overexpression of the cyclin D1 protein, and not to gene amplification. Yes

Published
2021

2. Prognostic and Clinicopathological Significance of FADD Upregulation in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

Author

González-Moles, Miguel Ángel, Ayén, Ángela, González-Ruiz, Isábel, de Porras-Carrique, Teresa, González-Ruiz, Lucía, Ruiz-Ávila, Isábel, Ramos-García, Pablo, [González-Moles,MA, González-Ruiz,I, de Porras-Carrique,T, Ramos-García,P] School of Dentistry, University of Granada, Granada, Spain. [González-Moles,MA, and Ramos-García,P] Instituto de Investigación Biosanitaria ibs.Granada, Granada, Spain. [Ayén,A] Dermatology Service, San Cecilio Hospital Complex, Granada, Spain. [González-Ruiz,L] Dermatology Service, Ciudad Real General University Hospital, Ciudad Real, Spain. [Ruiz-Ávila,I] Pathology Service, San Cecilio Hospital Complex, Granada, Spain.

Subjects
Proteína de dominio de muerte asociada a Fas, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Methods::Research Design::Meta-Analysis as Topic [Medical Subject Headings], Fas-associated death domain, Laryngeal squamous cell carcinoma, Information Science::Information Science::Information Services::Bibliography as Topic::Bibliometrics [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Chemicals and Drugs::Biological Factors::Biological Markers [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Odds Ratio [Medical Subject Headings], Metaanálisis, Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation::Gene Amplification [Medical Subject Headings], Phenomena and Processes::Metabolic Phenomena::Metabolism::Phosphorylation [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free Survival [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Intracellular Signaling Peptides and Proteins::Adaptor Proteins, Signal Transducing::Death Domain Receptor Signaling Adaptor Proteins::Fas-Associated Death Domain Protein [Medical Subject Headings], Revisión sistemática, Pronóstico, Carcinoma de células escamosas de cabeza y cuello, Head and neck squamous cell carcinoma, Biomarker, Prognosis, Meta-analysis, Biomarcadores, Oral squamous cell carcinoma, Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression Regulation::Up-Regulation [Medical Subject Headings], FADD, Systematic review, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings]
Abstract

Fas-associated death domain (FADD) upregulation, i.e., gene amplification, protein phosphorylation and/or overexpression, has shown promising prognostic implications in head and neck squamous cell carcinoma (HNSCC). This systematic review and meta-analysis aims to evaluate the clinicopathological and prognostic significance of FADD upregulation in HNSCC. We searched studies published before February 2020 through PubMed, Embase, Web of Science, Scopus and Google Scholar. We evaluated the quality of the studies included using the QUIPS tool. The impact of FADD upregulation on survival and clinicopathological variables was meta-analysed. We explored heterogeneity and their sources, conducted sensitivity analyses and investigated small-study effects. Thirteen studies (1,923 patients) met inclusion criteria. FADD immunohistochemical overexpression was statistically associated with worse overall survival (hazard ratio [HR] = 1.52, 95% confidence intervals [CI] = 1.28-1.81, p < 0.001), disease-specific survival (HR = 2.52, 95% CI = 1.61-3.96, p < 0.001), disease-free survival (HR = 1.67, 95% CI=1.29-2.15, p < 0.001), higher clinical stage (odds ratio [OR] = 1.72, 95% CI = 1.17-2.51, p = 0.005) and a large magnitude of effect with N+ status (OR = 2.36, 95% CI = 1.85-3.00, p < 0.001). FADD phosphorylation in ser-194 demonstrated no prognostic value, while no conclusive results can be drawn for FADD gene amplification. In conclusion, our findings indicate that immunohistochemical assessment of FADD overexpression could be incorporated into the prognostic evaluation of HNSCC. Yes

Published
2020

3. Prognostic and Clinicopathological Significance of CCND1 /Cyclin D1 Upregulation in Melanomas: A Systematic Review and Comprehensive Meta-Analysis.

Author

González-Ruiz, Lucía, González-Moles, Miguel Ángel, González-Ruiz, Isabel, Ruiz-Ávila, Isabel, Ramos-García, Pablo, and Nagore, Eduardo

Subjects
*MELANOMA prognosis, *PROTEINS, *BIOCHEMISTRY, *ONLINE information services, *META-analysis, *MEDICAL information storage & retrieval systems, *SYSTEMATIC reviews, *PHENOMENOLOGY, *MEDLINE
Abstract

Simple Summary: The incidence of cutaneous melanoma is increasing worldwide, currently responsible for 287,723 new cases and 60,712 deaths per year (GLOBOCAN, IARC, WHO). It should be also highlighted that some less frequent subtypes of melanomas—i.e., acral, uveal, and mucous melanoma—are responsible for significant morbidity associated with metastasis, responding typically worse to newer therapies. Therefore, new biomarkers are needed to improve the prognosis in individual patients. In this sense, the present study showed that CCND1/cyclin D1 upregulation is a common molecular oncogenic alteration in melanomas that probably favors the growth and expansion on cutaneous primary melanomas. Furthermore, immunohistochemical cyclin D1 overexpression strongly predicted a higher Breslow thickness, currently considered the most relevant prognostic factor in individual patients with melanomas. Finally, special attention should be paid to the CCND1/cyclin D1 complex in mucosal melanomas, whose upregulation was strikingly altered. Our objective was to evaluate the prognostic and clinicopathological significance of cyclin D1 (CD1) overexpression/CCND1 amplification in melanomas. We searched studies published before September 2019 (PubMed, Embase, Web of Science, Scopus). We evaluated the quality of the studies included (QUIPS tool). The impact of CD1 overexpression/CCND1 amplification on overall survival and relevant clinicopathological characteristic were meta-analyzed. We performed heterogeneity, sensitivity, small-study effects, and subgroup analyses. Forty-one studies and 3451 patients met inclusion criteria. Qualitative evaluation demonstrated that not all studies were performed with the same rigor, finding the greatest risk of bias in the study confounding domain. Quantitative evaluation showed that immunohistochemical CD1 overexpression had a statistical association with Breslow thickness (p = 0.007; OR = 2.09,95% CI = 1.23–3.57), significantly higher frequency of CCND1/cyclin D1 abnormalities has been observed in the primary tumor compared to distant metastases (p = 0.004), revealed also by immunohistochemical overexpression of the protein (p < 0.001; OR = 0.53,95% CI = 0.40–0.71), while the CCND1 gene amplification does not show association (p = 0.43); while gene amplification, on the contrary, appeared more frequently in distant metastases (p = 0.04; OR = 1.70,95% CI = 1.01–2.85) and not in the primary tumor. In conclusion, CCND1/cyclin D1 upregulation is a common molecular oncogenic alteration in melanomas that probably favors the growth and expansion of the primary tumor. This upregulation is mainly consequence to the overexpression of the cyclin D1 protein, and not to gene amplification. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results